Physician profile
Perrin D Royea
NPI 1285092908
$7,226.41
in general payments reported to CMS, 2019-2025
27 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $1,436 · 2023: $1,523 · 2024: $1,442 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,129 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.23 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,653.45 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $999.43 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $989.80 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $388.71 | 2021-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $372.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $247.65 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $159.16 | 2021-2025 | Suflave, Sutab |
| Pfizer INC. | $156.30 | 2023-2024 | |
| Genzyme Corporation | $151.89 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $117.78 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $104.85 | 2021-2025 | Ocaliva |
| Celltrion USA INC. | $97.10 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $94.59 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $90.10 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $88.67 | 2022-2023 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.17 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $69.41 | 2022-2023 | Rebyota |
| Fresenius Kabi USA, LLC | $69.00 | 2024 | Idacio |
| Daiichi Sankyo INC. | $55.87 | 2022 | |
| Vivus LLC | $54.27 | 2022-2024 | Pancreaze |
| Lilly USA, LLC | $54.02 | 2023-2024 | Omvoh |
| Gilead Sciences, INC. | $45.47 | 2025 | |
| Amgen INC. | $23.12 | 2022 | |
| Redhill Biopharma INC. | $20.46 | 2023 | Talicia, Aemcolo |
| Ipsen Biopharmaceuticals, INC | $19.55 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $18.50 | 2022 | |
| Celgene Corporation | $14.77 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perrin Royea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.